REmission induction of Arthritis caused by Cancer ImmunoTherapy (REACT): A Randomised, Multicentre Trial to Guide Initial Therapy for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

Research summary

The primary objective of the trial,to determine the proportion of patients in glucocorticoid-free ICI-IA remission 24 weeks from initiation of treatment,will be compared between the treatment arms using either a Chi-Squared or Fisher’s exact test (dependent on distributional assumptions). Moreover,we will use logistic regression models,adjusted for stratification variables and other baseline covariates deemed to be associated with the outcome (such as patient standard of care). This will allow us to present the treatment effect for each stratum of stratification variables,as well as attempt to distinguish efficacy effects relating to standard of care compared to those as a result of trial treatment.

Principal Investigator

Dr Shirish Dubey

Contact us

Email: gail.lang@ndorms.ox.ac.uk

IRAS number

1009034